ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 380,74
0,92%
Dow Jones
42 544,22
-0,07%
DAX
19 909,14
-0,25%
Brent Oil
73,855
-1,33%
Bitcoin
93 209,26
-0,19%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Evaxion Biotech AS (EVAX)

  7. Evaxion Biotech AS (EVAX) Actualités

EVAX

Evaxion Biotech AS (EVAX)

Evaxion Biotech AS
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EVAX
DateHeureSourceTitreSymboleSociété
30/12/202414h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
30/12/202414h00GlobeNewswire Inc.Evaxion announces plan to implement ADS ratio changeNASDAQ:EVAXEvaxion Biotech AS
17/12/202423h09Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
17/12/202414h00GlobeNewswire Inc.Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equityNASDAQ:EVAXEvaxion Biotech AS
12/12/202414h00GlobeNewswire Inc.Evaxion establishes new AI-derived precision cancer vaccine conceptNASDAQ:EVAXEvaxion Biotech AS
09/12/202414h00GlobeNewswire Inc.Evaxion announces 2025 milestones reflecting continued strong strategy executionNASDAQ:EVAXEvaxion Biotech AS
02/12/202414h00GlobeNewswire Inc.Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology CongressNASDAQ:EVAXEvaxion Biotech AS
18/11/202422h30Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
13/11/202414h00GlobeNewswire Inc.Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listingNASDAQ:EVAXEvaxion Biotech AS
12/11/202414h00GlobeNewswire Inc.Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1NASDAQ:EVAXEvaxion Biotech AS
31/10/202413h00GlobeNewswire Inc.Evaxion announces business update and third quarter 2024 financial resultsNASDAQ:EVAXEvaxion Biotech AS
28/10/202413h00GlobeNewswire Inc.Evaxion to announce business update and third quarter 2024 financial results on October 31NASDAQ:EVAXEvaxion Biotech AS
09/10/202414h00GlobeNewswire Inc.Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trialsNASDAQ:EVAXEvaxion Biotech AS
03/10/202414h00GlobeNewswire Inc.Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platformNASDAQ:EVAXEvaxion Biotech AS
26/09/202413h30GlobeNewswire Inc.Evaxion significantly expands vaccine development collaboration with MSDNASDAQ:EVAXEvaxion Biotech AS
19/09/202414h00GlobeNewswire Inc.Evaxion launches improved AI-Immunology™ platform for vaccine antigen predictionNASDAQ:EVAXEvaxion Biotech AS
16/09/202413h00GlobeNewswire Inc.Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01NASDAQ:EVAXEvaxion Biotech AS
09/09/202414h00GlobeNewswire Inc.Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01NASDAQ:EVAXEvaxion Biotech AS
09/09/202413h00GlobeNewswire Inc.Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2NASDAQ:EVAXEvaxion Biotech AS
23/08/202414h30Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVAXEvaxion Biotech AS
23/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVAXEvaxion Biotech AS
14/08/202413h00GlobeNewswire Inc.Evaxion Announces Business Update and Second Quarter 2024 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
12/08/202413h27GlobeNewswire Inc.Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14NASDAQ:EVAXEvaxion Biotech AS
08/08/202414h00GlobeNewswire Inc.Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in SeptemberNASDAQ:EVAXEvaxion Biotech AS
16/07/202413h30GlobeNewswire Inc.Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology ConferenceNASDAQ:EVAXEvaxion Biotech AS
03/07/202414h05GlobeNewswire Inc.Evaxion Reinforces Milestone Timeline and Provides Shareholder UpdateNASDAQ:EVAXEvaxion Biotech AS
26/06/202413h30GlobeNewswire Inc.Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification MethodNASDAQ:EVAXEvaxion Biotech AS
17/06/202414h44GlobeNewswire Inc.Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical JournalNASDAQ:EVAXEvaxion Biotech AS
03/06/202414h00GlobeNewswire Inc.Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
28/05/202414h21GlobeNewswire Inc.Evaxion Announces Business Update and First Quarter 2024 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
 Showing the most relevant articles for your search:NASDAQ:EVAX

Dernières Valeurs Consultées

BIT
3PYP
Leverage Shares 3X PAYPAL
BIT
BSRID
Exchange Traded
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés